[Effects of cefotaxime single administration and of cefotaxime + fosfomycin administration against respiratory tract infections].
Subjects in a cefotaxime (CTX) single administration group and in a CTX + fosfomycin (FOM) administration group were randomly selected for a comparative study on the utility of each product against respiratory tract infections. Overall improvement rates were 81.3% in 32 cases of the CTX single administration group, and 75.6% in 41 cases of the CTX + FOM concomitant administration group. No statistical difference was observed. As for adverse reactions and abnormal laboratory test results, pyrexia, thrombocytopenia, increases in GOT and GPT, and increase in GPT were observed in 4 cases of the CTX single administration group, while angialgia, increases in GOT and GPT (3 cases), and increases in BUN, (totalling 5), were observed in the CTX + FOM group. However, all the symptoms were transient, and none was serious in nature.
Shimokata
K
K
First Department of Internal Medicine, School of Medicine, Nagoya University.
Torigai
K
K
Kato
M
M
Sakai
S
S
Nomura
F
F
Ito
T
T
Saka
H
H
Senda
Y
Y
Torii
Y
Y
Ito
T
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002439:Cefotaxime / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D005578:Fosfomycin / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D005578:Fosfomycin; D002439:Cefotaxime